 |
| Osteoarthritis Drugs Market |
The most prevalent type of arthritis is osteoarthritis, which is sometimes referred to as a degenerative joint disease. Different joints in the body may be affected. The condition, however, significantly affects the minor joints in the fingers, the neck, the lower back, the hips, and the knees. The older population is more likely to suffer from osteoarthritis, a severely disabling form of joint disease. Particularly in populations with low levels of physical activity or a high body mass index, the disease is a slow, protracted process that results in bad quality of life, function loss, and moderate to severe discomfort (BMI). Pathologically, Osteoarthritis Drugs Market is characterized by regional cartilage loss, surrounding bone remodeling, and related inflammation. A joint may need to heal itself in response to a number of injuries.
It
is projected that the COVID-19 outbreak will have a minor impact on the market
for osteoarthritis treatments. Osteoarthritis Drugs Market is one kind of medication whose use has
decreased. There may be a decrease in immunological response for up to a few
weeks after receiving corticosteroid injections, despite the fact that there is
no evidence to support a significant increase in the risk of infection.
Although this danger is quite minimal, it must be taken into account when
determining whether to move forward with the treatment.
The substantial proportion of this market segment can be ascribed to the rising prevalence of osteoarthritis, geriatrics, and obesity in various European nations, as well as the rising number of injuries from sports and auto accidents.
The
global market for Osteoarthritis
Drugs Market
therapeutics is being driven by two factors: the rising elderly population and
the rising number of pharmacological approvals for the treatment of
osteoarthritis pain.
The market for
osteoarthritis treatments is growing rapidly as a result of the increasing
prevalence of osteoarthritis, particularly hip, and knee osteoarthritis.
Drugs for Osteoarthritis:
Global Competitive Landscape
Pfizer, Inc., Abbott, Eli Lilly, and Company, BIOGEN PHARMA S.p.A., Horizon Therapeutics plc, Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Sanofi, Regeneron, GlaxoSmithKline Plc., Johnson & Johnson Private Limited, Bayer AG, Novartis AG, Ferring B.V., Pacira Pharmaceuticals, Inc, Zimmer Biomet,
Comments
Post a Comment